An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining

被引:1
作者
Jokinen, Jeremy D. [1 ]
Lievano, Fabio [1 ]
Scarazzini, Linda [1 ]
Truffa, Melissa [1 ]
机构
[1] Abbvie Inc, GM60,AP51-2,1 N Waukegan Rd, N Chicago, IL 60064 USA
关键词
pharmacovigilance; data mining; signal detection; safety statistics; disproportionality; EVENT REPORTING SYSTEM; SIGNAL-DETECTION; PERFORMANCE; TRIAGE;
D O I
10.1177/2168479017728986
中图分类号
R-058 [];
学科分类号
摘要
Background: Safety surveillance relies on mining of large pharmacovigilance (PV) databases to generate insights regarding the safe use of pharmaceutical products. The predominant approach to PV data mining involves computation of disproportionality scores for drug-adverse event (drug-AE) pairs. However, this approach requires a database to be sufficiently large, sufficiently diverse for the analysis to be reliably sensitive and specific, and fails to consider the particular safety profile of a product. Objective: The present study proposes and tests a novel, frequency-based approach to PV data mining that (1) leverages product knowledge and historical drug-AE trends and (2) imposes no requirement for the size and diversity of the database to which it is applied. Method: A focus group of physicians and scientists was convened to identify quantitative characteristics of data trends that they consider informative when reviewing counts of adverse events for products under surveillance. Feedback was transferred into a series of decision rules that, when applied to adverse event counts, identifies adverse event trends that are classified as Continuing Trend, Emerging Trend, or No Trend. Regression analyses are completed to verify the presence of a linear trend; and categorical measures of association completed to compare this frequency-based approach to disproportionality scores in a simulated database. Results: A significant, positive linear trend is present for the Continuing Trend and Emerging Trend categories (P < .0001). There is a significant association between trend categorizations and disproportionality scores (P < .0001). Conclusion: The proposed alternative frequency-based method for PV data mining would be useful where disproportionalities scores are not appropriate. Additionally, this method may be useful in conjunction with disproportionality scores, where appropriate, highlighting adverse events that are both reported disproportionately and have increasing trends.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 50 条
  • [21] Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance
    Xu, Xuan
    Kawakami, Jessica
    Gedara, Nuwan Indika Millagaha
    Riviere, Jim E.
    Meyer, Emma
    Wyckoff, Gerald J.
    Jaberi-Douraki, Majid
    [J]. ELIFE, 2021, 10
  • [22] Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors
    Eskildsen, Nadine Kadi
    Eriksson, Robert
    Christensen, Sten B.
    Aghassipour, Tamilla Stine
    Bygso, Mikael Juul
    Brunak, Soren
    Hansen, Suzanne Lisbet
    [J]. BMC MEDICAL INFORMATICS AND DECISION MAKING, 2020, 20 (01)
  • [23] Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors
    Nadine Kadi Eskildsen
    Robert Eriksson
    Sten B. Christensen
    Tamilla Stine Aghassipour
    Mikael Juul Bygsø
    Søren Brunak
    Suzanne Lisbet Hansen
    [J]. BMC Medical Informatics and Decision Making, 20
  • [24] Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre
    Gahr, Maximilian
    Zeiss, Rene
    Lang, Dirk
    Connemann, Bernhard J.
    Schoenfeldt-Lecuona, Carlos
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (07) : 768 - 773
  • [25] Data Mining in Pharmacovigilance Practice: Which Algorithm to Use?
    X. Yang
    J. Freeman
    R. Bwire
    [J]. Drug Safety, 2008, 31 : 885 - 885
  • [26] Data Mining in Pharmacovigilance Practice: Which Algorithm to Use?
    Yang, X.
    Freeman, J.
    Bwire, R.
    [J]. DRUG SAFETY, 2008, 31 (10) : 888 - 888
  • [27] Influence of the MedDRA® hierarchy on pharmacovigilance data mining results
    Pearson, Ronald K.
    Hauben, Manfred
    Goldsmith, David I.
    Gould, A. Lawrence
    Madigan, David
    O'Hara, Donald J.
    Reisinger, Stephanie J.
    Hochberg, Alan M.
    [J]. INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2009, 78 (12) : E97 - E103
  • [28] Editorial: Leveraging pharmacovigilance data mining with "the patient" in mind
    Gossell-Williams, Maxine
    Salas, Maribel
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Data mining study on adverse events of tirzepatide based on FAERS database
    Huo, Yan
    Ma, Minghua
    Liao, Xiaolan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [30] Mining the Web of Life Sciences Linked Open Data for Mechanism-Based Pharmacovigilance
    Kamdar, Maulik R.
    [J]. COMPANION PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE 2018 (WWW 2018), 2018, : 861 - 865